Health Condition 1: null- Allergic rhinitis Health Condition 2: J309- Allergic rhinitis, unspecified
Conditions
Interventions
Intervention1: Acrivastine 8 mg capsules: One capsule thrice daily for 2 weeks
Control Intervention1: Chlorpheniramine maleate 4 mg tablets: One tablet thrice daily for 2 weeks
Sponsors
Cadila Healthcare Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex of 18 to 65 years of age 2. Established diagnosis of allergic rhinitis 3. Informed consent
Exclusion criteria
Exclusion criteria: 1. Pregnancy & Lactation. 2. Significant renal impairment. 3. Narrow-angle glaucoma, GI or GUT obstruction. 4. Patients with acute attack of bronchial asthma or those on corticosteroids. 5. Nasal structural abnormalities 6. Upper respiratory tract infection 7. Hypersensitivity to study medications 8. Patients with any other serious concurrent illness or malignancy 9. Continuing history of alcohol and / or drug abuse 10. Recent participation in another clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in the total symptom scoreTimepoint: 0,1,2 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The change in the total and individual nasal and ocular symptom scoresTimepoint: 0,1,2 weeks | — |
Countries
India
Contacts
Public ContactDr Ravindra Mittal
Cadila Healthcare Ltd.
Outcome results
None listed